Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. RELVENE (o-(betahydroxyéthyl) - rutosides)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

RELVENE (o-(betahydroxyéthyl) - rutosides)

Medicine - Posted on Jun 08 2005 - Updated on Jun 12 2019
Active substance (DCI)
  • o-(betahydroxyéthyl) - rutosides
history (2)
  • 6/8/05

    RELVENE 1000 mg, poudre pour solution buvable en sachet-dose B/20 (CIP 309 035.7) RELVENE 4 POUR CENT, solution buvable Flacon de 90 ml (code CIP : 3090340)

    RELVENE 1000 mg, poudre pour solution buvable en sachet-dose B/20 (CIP 309 035.7) RELVENE 4 POUR CENT, solution buvable Flacon de 90 ml (code CIP : 3090340)
    icône flèche
  • 6/8/05

    RELVENE 2 %, gel localTube de 60 g, Boîte de 1 (Code CIP : 309 030 5)

    RELVENE 2 %, gel localTube de 60 g, Boîte de 1 (Code CIP : 309 030 5)
    icône flèche
Technical information
Manufacturer
EXPANSCIENCE
Presentation

RELVENE 4 POUR CENT, solution buvable
Flacon de 90 ml - Code CIP : 309 034-0

RELVENE 1000 mg, poudre pour solution buvable en sachet-dose
B/20 - Code CIP : 309 035-7

All our publications
    Drug therapy Peripheral vascular diseases Skin and connective tissue diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
DERsJYQmmdMU44VS